CXCL10 and glioblastoma: At the same time, the CXCL10 chemokine can activate the body’s systemic immunity and enrich T cells to kill residual tumor cells, ultimately significantly inhibiting the recurrence of GBM and prolonging the survival period of mice (Zhang J. et al., 2021).